Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

December 29, 2023

Study Completion Date

March 29, 2026

Conditions
Gastric Cancer Stage III
Interventions
DRUG

Camrelizumab

Camrelizumab, 200 mg IV for 30-60 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.

DRUG

Oxaliplatin

Oxaliplatin: 130 mg/m\^2 IV for 2-6 hour in first day which will be administered at least 30 min after completion of camrelizumab administration, every 3 weeks. Repeated every 21 days, 21 days for a cycle.

DRUG

Tegafur gimeracil oteracil potassium capsule

Tegafur gimeracil oteracil potassium capsule: 80 mg/m\^2 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Repeated every 21 days. 21 days for a cycle.

Trial Locations (4)

310003

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

317000

Taizhou Hospital, Taizhou

323000

Lishui Central Hospital, Lishui

325027

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

Yu jiren

OTHER